{
    "root": "0dcf2f70-92d9-c24b-9787-0d395e04b46f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "SEMGLEE",
    "value": "20250303",
    "ingredients": [
        {
            "name": "INSULIN GLARGINE",
            "code": "2ZM8CX04RZ"
        },
        {
            "name": "ZINC CHLORIDE",
            "code": "86Q357L16B"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "METACRESOL",
            "code": "GGO4Y809LO"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH"
        }
    ],
    "indications": "semglee indicated improve glycemic control adult pediatric patients diabetes mellitus . limitations semglee recommended treatment diabetic ketoacidosis .",
    "contraindications": "individualize based metabolic needs , blood glucose monitoring , glycemic control , type diabetes , prior insulin . ( 2.2 ) administer subcutaneously abdominal area , thigh , deltoid daily time day , time every day . ( 2.1 ) dilute mix insulin solution . ( 2.1 ) rotate injection sites reduce risk lipodystrophy localized cutaneous amyloidosis . ( 2.1 ) full prescribing information recommended starting patients type 2 diabetis ( 2.3 ) change semglee insulins . ( 2.4 ) closely monitor glucose switching semglee initial weeks thereafter . ( 2.4 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "semglee contraindicated : •during episodes hypoglycemia [ ( 5.3 ) ] . •in patients hypersensitivity insulin glargine products excipients semglee [ ( 5.5 ) ] .",
    "indications_original": "SEMGLEE is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.\n                  \n                     Limitations of Use \n                  \n                  SEMGLEE is not recommended for the treatment of diabetic ketoacidosis.",
    "contraindications_original": "Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. ( 2.2 ) Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time of day, but at the same time every day. ( 2.1 ) Do not dilute or mix with any other insulin or solution. ( 2.1 ) Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. ( 2.1 ) See Full Prescribing Information for the recommended starting dosage in patients with type 2 diabetis ( 2.3 ) and how to change to SEMGLEE from other insulins. ( 2.4 ) Closely monitor glucose when switching to SEMGLEE and during initial weeks thereafter. ( 2.4 )",
    "adverseReactions_original": "SEMGLEE is contraindicated: \n                  \n                     \n                        •During episodes of hypoglycemia [see Warnings and Precautions (5.3)]. \n                     \n                     \n                        •In patients with hypersensitivity to insulin glargine products or any of the excipients in SEMGLEE [see Warnings and Precautions (5.5)]."
}